SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+11.17%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$900M
AUM Growth
+$900M
(+11%)
Cap. Flow
-$78M
Cap. Flow
% of AUM
-8.67%
Top 10 Holdings %
Top 10 Hldgs %
42.92%
Holding
115
New
38
Increased
26
Reduced
29
Closed
13
Top Buys
| 1 |
Teva Pharmaceuticals
TEVA
|
$32M |
| 2 |
United Therapeutics
UTHR
|
$23.5M |
| 3 |
Humana
HUM
|
$17.4M |
| 4 |
Surmodics
SRDX
|
$13.9M |
| 5 |
The Beauty Health Co
SKIN
|
$11.6M |
Top Sells
| 1 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$51.8M |
| 2 |
Exact Sciences
EXAS
|
$36.3M |
| 3 |
Smith & Nephew
SNN
|
$15.5M |
| 4 |
SI-BONE Inc
SIBN
|
$11.7M |
| 5 |
Vericel Corp
VCEL
|
$9.75M |
Sector Composition
| 1 | Healthcare | 96.82% |
| 2 | Consumer Staples | 2.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BCYC
26
Bicycle Therapeutics
BCYC
$492M
| $10.5M | 1.17% |
411,800
| – | – |
|
27
NovoCure
NVCR
$1.35B
| $10.2M | 1.13% |
245,100
+115,100
| +89% | +$4.78M |
|
|
RETA
28
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $9.95M | 1.11% |
97,547
-77,045
| -44% | -$7.86M |
|
29
Seres Therapeutics
MCRB
$162M
| $9.8M | 1.09% |
+102,299
| New | +$9.8M |
|
30
Bausch Health
BHC
$2.72B
| $9.24M | 1.03% |
+1,155,500
| New | +$9.24M |
|
31
Nuvalent
NUVL
$5.74B
| $8.98M | 1% |
213,000
-23,900
| -10% | -$1.01M |
|
32
Iovance Biotherapeutics
IOVA
$800M
| $8.73M | 0.97% |
1,239,777
-210,000
| -14% | -$1.48M |
|
33
Illumina
ILMN
$15.2B
| $8.61M | 0.96% |
+47,185
| New | +$8.61M |
|
34
Natera
NTRA
$23B
| $8.21M | 0.91% |
168,800
-125,400
| -43% | -$6.1M |
|
35
AngioDynamics
ANGO
$432M
| $8.02M | 0.89% |
768,500
+543,500
| +242% | +$5.67M |
|
|
THER
36
DELISTED
THERATECHNOLOGIES INC COM
THER
| $7.85M | 0.87% |
9,325,511
+235,000
| +3% | +$198K |
|
37
C4 Therapeutics
CCCC
$182M
| $7.4M | 0.82% |
2,692,020
+305,000
| +13% | +$839K |
|
38
Evolus
EOLS
$477M
| $7.39M | 0.82% |
+1,017,000
| New | +$7.39M |
|
39
Kiniksa Pharmaceuticals
KNSA
$2.63B
| $7.32M | 0.81% |
+519,640
| New | +$7.32M |
|
|
40
Exact Sciences
EXAS
$9.33B
| $6.53M | 0.73% |
69,500
-387,000
| -85% | -$36.3M |
|
41
BridgeBio Pharma
BBIO
$9.91B
| $6.26M | 0.7% |
364,000
| – | – |
|
42
Transmedics
TMDX
$3.65B
| $6.23M | 0.69% |
74,200
+55,200
| +291% | +$4.64M |
|
43
Alkermes
ALKS
$4.95B
| $6.08M | 0.68% |
194,400
-35,600
| -15% | -$1.11M |
|
44
Pharvaris
PHVS
$1.41B
| $5.93M | 0.66% |
391,900
+55,000
| +16% | +$833K |
|
45
Tango Therapeutics
TNGX
$745M
| $5.9M | 0.66% |
+1,776,897
| New | +$5.9M |
|
46
Viking Therapeutics
VKTX
$3.02B
| $5.46M | 0.61% |
336,700
-123,300
| -27% | -$2M |
|
47
Xeris Biopharma Holdings
XERS
$1.27B
| $5.38M | 0.6% |
+2,054,105
| New | +$5.38M |
|
|
AVDL
48
Avadel Pharmaceuticals
AVDL
$1.45B
| $5.06M | 0.56% |
+307,000
| New | +$5.06M |
|
49
BioMarin Pharmaceuticals
BMRN
$11.3B
| $5.01M | 0.56% |
+57,800
| New | +$5.01M |
|
50
Mirum Pharmaceuticals
MIRM
$3.75B
| $4.55M | 0.51% |
176,000
-66,000
| -27% | -$1.71M |
|